Facet Biotech investor buys more shares, boosts ownership to 14.99%

By Lisa Kerner

Charlotte, N.C., Sept. 29 - A group of investors led by Biotechnology Value Fund, LP bought 367,100 shares of Facet Biotech Corp. between July 27 and Sept. 8 priced from $8.25 to $16.25 each, according to a schedule 13D filed on Tuesday with the Securities and Exchange Commission.

The investors beneficially own 3,683,521 shares, or 14.99%, of the Cambridge, Mass.-based pharmaceutical company.

As previously reported, Biogen Idec Inc.'s $14.50-per-share cash tender offer for Facet's outstanding shares ends on Oct. 19. Biogen announced the offer on Sept. 21.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.